Bicara Therapeutics Inc. · NASDAQ:BCAX
Bicara Therapeutics — Q2 2026 Earnings Presentation
8 slides from Bicara Therapeutics's earnings presentation, Aug 11, 2026
Slide 1: Q2 2026 Earnings Call
Q2 2026 Earnings Call August 11, 2026 © 2024 – 2026 Bicara Therapeutics
Slide 2: Forward-looking statements
Forward-looking statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements other than historical factual information are forward-looking statements, including without limitation express or implied statements regarding our strateg
Slide 3: Agenda & today's presenters
Agenda & today’s presenters 1 Introduction & Leadership Announcements Claire Mazumdar, Ph.D., MBA Chief Executive Officer 2 Business Updates Ryan Cohlhepp, Pharm.D. President & Chief Operating Officer 3 Financial Results Ivan Hyep, MBA Chief Financial Officer 3
Slide 4: Strategic leadership transitions marking next era of execution and growth
Strategic leadership transitions marking next era of execution and growth Ryan Cohlhepp, Pharm.D. Claire Mazumdar, Ph.D., Tanya Green Jenn Larson, CPA Jenna Cohen Greg Shiferman, J.D. MBA President & Chief Operating Chief Development Officer Former Chief Financial Officer of Chief Corporate Affairs
Slide 5: Strategic priorities to drive success
Strategic priorities to drive success Preparing for commercial Executing a strategic Continuing to strengthen our success development plan for FICERA people and culture Laying the foundation to achieve Advancing FICERA’s development Continuing to build the talent, FICERA’s blockbuster potential with
Slide 6: Q2 2026 highlights and recent progress
Q2 2026 highlights and recent progress ASCO 2026: Three-year follow-up data showed FICERA's TGF-β inhibition drives 1 tumor penetration, delivering unprecedented deep and durable responses and nearly doubling overall survival versus standard of care Continued strong execution in FORTIFI-HN01 pivotal
Slide 7: Strong financial position to support strategic investment
Strong financial position to support strategic investment (in millions) Three Months Ended Six Months Ended Statement of Operations June 30, June 30, (Unaudited) 2026 2025 2026 2025 Total operating expenses Research & development1 $ 45.8 $ 24.8 $ 93.2 $ 59.1 General & administrative2 $ 14.2 $ 7.2 $
Slide 8: Thank You
BICARA THERAPEUTICS” Thank You